Video Interview: Synthetic Biologics CEO Outlines Plan For Lead Assets
This article was originally published in Scrip
Executive Summary
Synthetic Biologics CEO Jeffrey Riley outlines to Pharma Intelligence senior editor Sten Stovall how the clinical stage developer of therapeutics to protect the gut microbiome while targeting pathogen-specific diseases plans to advance its pipeline, which currently contains two lead candidates in Phase II. The most advanced, SYN-004, is designed to protect the gut microbiome from the effects of certain commonly used intravenous beta-lactam antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD). Meanwhile, SYN-010 aims to reduce the impact of methane producing organisms in the gut.